Globally, antidepressant usage has been on the rise. As of 2022, among select Organization for Economic Cooperation and Development (OECD) countries, Iceland, Portugal, and the UK were the biggest consumers of antidepressants. At that time, people in Iceland consumed antidepressants at a rate of about 157 defined daily doses (DDD) per 1,000 people.

Mental health globally

Mental health disorders affect a significant proportion of the population, though addressing and understanding the prevalence of mental health is difficult due to regional differences in diagnostic criteria and understandings of mental health. Despite barriers to gathering data on mental health, there have been some global quantitative studies to help better understand certain conditions. It is suggested that mental health is among the top three health concerns among adults worldwide. Recent estimates suggest that about 13 percent of the overall population suffers from some mental health or substance use disorder.

Depression and anxiety globally

A global survey on depression and anxiety showed that the largest numbers of people with anxiety resided in locations in South-East Asia and the Americas. However, the highest distribution of cases of depression globally is among populations in South-East Asia and the Western Pacific. Both depression and anxiety disproportionately affect women in all regions of the world.

In 2022, more than three million people were treated with antidepressants or mood regulating medicine in France, while not having a pathology diagnosed. With roughly 897,500 patients, the number of people treated with such medication was the highest within the age group 35 to 54 years old.

In 2022, there were an estimated 5,863 overdose deaths in the U.S. from antidepressants, an increase from 1,798 deaths in 2000. This statistic presents the number of overdose deaths from antidepressants in the U.S. from 1999 to 2022.

The pharmaceutical consumption of antidepressants in Slovenia increased by 2.3 defined daily doses per 1,000 inhabitants per day (+3.48 percent) since the previous year. Therefore, the consumption in Slovenia reached a peak in 2022 with 68.4 defined daily doses per 1,000 inhabitants per day. Notably, the consumption in this industry continuously increased over the last years.Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

According to cognitive market research, the global antidepressant drugs market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

Antidepressants are physician-recommended medications to treat depression. Depression is more than just a few days of moderate sadness.
 Antidepressant market growth has been positively influenced by the COVID-19 epidemic because of an increase in product sales related to the disaster.
The drug class segment is divided into reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin antagonists, and others.
The major depressive disorder segment dominated the market, with a market share of xx% in 2024.
The route of administration segment is divided into oral and injectable. The oral segment dominated the market, with a market share of xx% in 2024.
The hospital pharmacy segment dominated the market, with a market share of xx% in 2024.
North America garnered a major share in the antidepressant drugs market in 2024 and is expected to continue to dominate during the forecast period

Market Dynamics of the Antidepressant Drugs Market

Key Drivers of the Antidepressant Drugs Market

Growing awareness and reduced stigma will significantly expand the market growth

The growing awareness of psychological health concerns and the initiatives to lessen the stigma associated with seeking treatment are major factors propelling the market for antidepressant medications. Public knowledge of psychological health concerns, such as anxiety and depression, has grown as a result of developing awareness campaigns and educational initiatives. The number of individuals who identify the signs of mental health disorders and seek professional treatment will rise, which will raise the need for antidepressant drugs. Educating the public about mental health illnesses, accessible treatments, and the need to get assistance is the aim of educational efforts and programs. Media campaigns that feature true tales, celebrity endorsements, and accurate portrayals of psychological health issues contribute to public awareness.

Increased destigmatization of mental health issues propelling the market growth

As society's perceptions of mental health shift, there is a growing understanding of the prevalence and consequences of mental health conditions, such as anxiety and depression. This changing view has led more people to seek care for mental health difficulties, increasing the demand for effective therapy. Moreover, the reduced stigma has encouraged pharmaceutical companies to invest in the development of new, more potent antidepressants. To satisfy the needs of numerous patients, the industry has expanded to provide a greater range of treatment options.

• For instance, the data updated by the National Institute of Mental Health (NIMH) in January 2022 shows depression is one of the most common mental health disorders in the US, and an estimated 46.9% of adolescents with a major depressive episode and significant impairment received treatment in the previous year. (Source:https://www.nimh.nih.gov/health/statistics/mental-illness )

Restraints of the Antidepressant Drugs Market

Side effects and safety concerns of antidepressant drugs may hamper the market growth

Patients may be reluctant to begin or continue antidepressant medication due to worries about potential side effects and their general well-being. Reduced market development and poorer solution rates may result from patient resistance and non-compliance. Regulations and warning labels have the potential to negatively affect consumers' perceptions and reduce their belief in the safety of antidepressant drugs, which can hinder the growth of the market. Unfavorable events and health issues may lead to legal actions and lawsuits against medication companies. Legal disputes may be detrimental to a business's profits, the reputation of an antidepressant, and consumer trust.

How Did COVID-19 Impact the Antidepressant Drugs Market

Antidepressant market growth has been positively influenced by the COVID-19 epidemic because of an increase in product sales related to the disaster. Furthermore, the market expansion has been helped by important tactics used by biotechn...

The pharmaceutical consumption of antidepressants in Spain increased by 5.7 defined daily doses per 1,000 inhabitants per day (+6.15 percent) in 2022. Therefore, the consumption in Spain reached a peak in 2022 with 98.4 defined daily doses per 1,000 inhabitants per day. Notably, the consumption in this industry continuously increased over the last years.Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

Forecast: Antidepressant Medicine Sales in Denmark 2022 - 2026 Discover more data with ReportLinker!

This statistic displays the leading ten antidepressant drugs dispensed in England, in 2023, by number of prescription items. In that year, there were over 23 million items of the antidepressant sertraline hydrochloride dispensed.

Data and code supporting the article:

Impact of the COVID-19 pandemic on antidepressant use in eleven European regions: a comparative time series analysis 2018–2022

Prescription, prevalence and incidence data from January 2018 to December 2022 for Croatia, the Czech Republic, Finland, Germany, Slovenia, Sweden, and the United Kingdom (England, Northern Ireland, Scotland, and Wales).Data include the numbers of dispensed defined daily doses (DDDs) and packs, aggregated by country and month, and prevalence and incidence of antidepressant dispensing.

For more information, see the accompanying document ReadMe.md.

In 2022, the pharmaceutical consumption of antidepressants in Estonia increased by 3.8 defined daily doses per 1,000 inhabitants per day (+9.34 percent) since 2021. With 44.5 defined daily doses per 1,000 inhabitants per day, the consumption thereby reached its highest value in the observed period. Notably, the consumption in this industry continuously increased over the last years.Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

In 2022, the pharmaceutical consumption of antidepressants in Portugal increased by 11.7 defined daily doses per 1,000 inhabitants per day (+8.43 percent) since 2021. Therefore, the consumption in Portugal reached a peak in 2022 with 150.5 defined daily doses per 1,000 inhabitants per day. Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

Forecast: Antidepressant Medicine Sales in Austria 2022 - 2026 Discover more data with ReportLinker!

IntroductionSelf-harm represents a complex and multifaceted public health issue of global significance, exerting profound effects on individuals and communities alike. It involves intentional self-poisoning or self-injury with or without the motivation to die. Although self-harm is highly prevalent, limited research has focused on the patterns and trends of self-harm among hospital populations in low- and middle-income countries, particularly within Africa. This study aims to explore the socio-demographic and clinical profile of patients presenting with self-harm and determine the common self-harm patterns at a tertiary facility in Kenya.MethodologyWe carried out a descriptive retrospective study and included patients from inpatient units and outpatient settings within the Secion of Psychiatry at the Aga Khan University Hospital, Nairobi from January 1st 2018 to December 31st 2022. A data abstraction tool was used to collect data from eligible files sourced from the medical records department for all patients who met the study criteria. Summary statistics were reported as frequencies and percentages for categorical data and as means and standard deviations for continuous data.ResultsA total of 507 files were reviewed in the given timeframe and 497 patients were included in the analysis. Of these patients, 28.1% (n = 144) presented with self-harm. The mean age of the self-harm patients was 26.5 years (SD = 10.5) and a majority (74.3%) were female. The first point-of-contact was at the emergency department in 72.9% of the cases. A majority of them, i.e. 89.6%, reported a past psychiatric diagnosis. Based on the psychiatric diagnosis evaluation of the patients- depression was the most common diagnosis at 88.2%, followed by anxiety disorder at 27.8% and bipolar mood disorder at 17.4%. The majority of reported self-harm cases involved overdose incidents (68.8%), with self-injury accounting for 56.3% of cases. Analgesics were the most frequently reported type of overdose, followed by tricyclic antidepressants. In context of self-injury, cutting emerged as the predominant form of self-harm. Family conflict was reported to be the most common reason for self-harm at 39.6%.ConclusionThis study shows a high rate of self-harm among patients with mental illness in this facility, necessitating the development of self-harm prevention and management protocols. A national registry of self-harm behavior would also help further elucidate the occurrence and mechanisms of self-harm in the population, improving the possibility for early interventions and prevention.

Demographic characteristics of all patients and in comparison, with self-harm and non-self-harm patients.

During the 2022-2023 school year, 20 percent of university and college students in the U.S. reported that in the past year they had been using antidepressant medications regularly. This statistic shows the percentage of postsecondary students using psychotropic medications in the United States in 2022-2023.

Forecast: Antidepressant Medicine Sales in Belgium 2022 - 2026 Discover more data with ReportLinker!

Forecast: Antidepressant Medicine Sales in Ireland 2022 - 2026 Discover more data with ReportLinker!

Forecast: Antidepressant Medicine Use in Canada 2022 - 2026 Discover more data with ReportLinker!

Forecast: Antidepressant Medicine Use in Australia 2022 - 2026 Discover more data with ReportLinker!

Snapshot img

Binge-Eating Disorder Treatment Market Size 2024-2028

The binge-eating disorder treatment market size is forecast to increase by USD 568.7 million, at a CAGR of 6.78% between 2023 and 2028.

The market is witnessing significant growth due to several key factors. The increasing prevalence of the disorder is a major driver for market expansion. Another growth factor is the development and approval of new drugs for treating this disorder. For instance, Topiramate and Lisdexamfetamine are FDA-approved medications for the treatment. However, the side effects of these drugs, such as insomnia, dizziness, and dry mouth, may hinder market growth. It is essential for market players to focus on developing effective treatments with minimal side effects to cater to the growing demand for binge-eating disorder treatment.

What will be the Size of the Binge-Eating Disorder Treatment Market During the Forecast Period?

Request Free Sample

The market encompasses a range of interventions addressing excessive feeding and related psychological and physical issues. BED, a type of eating disorder, is characterized by recurrent episodes of consuming large quantities of food in a short period, often accompanied by feelings of guilt, depression, or shame. This disorder can co-occur with bulimia, other eating disorders, and various comorbid medical conditions, such as obesity, diabetes, hypertension, chronic pain, and general medical illnesses. The market incorporates both pharmacological and psychological approaches. Medications, including those targeting obesity, may be used to manage weight and associated health complications.
Psychological interventions, like cognitive-behavioral therapy, aim to address the underlying emotional and behavioral drivers of binge eating. Additionally, integrated care models that combine medical and psychological treatments have gained traction in addressing the complex nature of BED and its comorbid disorders. The market is expected to grow due to increasing awareness, rising prevalence, and improving diagnostic tools. According to various studies, BED affects a significant portion of the population, with normal weight, overweight, and obese individuals being affected. The market's growth is also driven by the recognition of the significant impact of BED on overall health and quality of life.

How is this Binge-Eating Disorder Treatment Industry segmented and which is the largest segment?

The binge-eating disorder treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Offline
  Online


Type

  Antidepressants
  Anticonvulsants
  Stimulants and others


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    India


  Rest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period.

The market in 2023 was primarily dominated by the offline sector, accounting for the largest market share. Offline distribution channels are preferred by most customers due to product assurance, authenticity, and verification. Offline retailers provide convenience, personalization, and personal support, contributing to segment growth. Brick-and-mortar stores offer advantages such as geographical presence, ease of production and inventory management, and goods transportation, making them a preferred choice for market players. The increased footfall in offline stores has led companies to invest in physical retail stores to sell binge-eating disorder treatment medications. Comorbid conditions, including anxiety disorders, mood disorders, impulse-control disorders, substance use disorders, general medical illnesses such as obesity, diabetes, hypertension, chronic pain, and psychiatric disorders, often accompany binge-eating disorder.

Treatment options include psychotherapy, medications like antidepressant drugs and lisdexamfetamine with methylphenidate, and healthcare services. The market is expected to witness growth due to the rising prevalence of these disorders and the increasing awareness and acceptance of mental health issues. The costly nature of treatment and the availability of alternative, less expensive options may pose challenges to market growth. Upcoming clinical trials for medications such as centanafadine sustained-release tablets, serotonergic antidepressants, solriamfetol, and dasotraline offer potential opportunities for market expansion.

Get a glance at the Binge-Eating Disorder Treatment Industry report of share of various segments Request Free Sample

The offline segment was valued at USD 809.60 million in 2018 and showed a gradual increase during the forecast period.

Regional Ana